Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM772MW)

Drug Name

Fazirsiran Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Alpha-1 antitrypsin deficiency	5C5A	Phase 3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting SERPINA1 messenger RNA (SERPINA1 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARO-AAT	DM2UP6Z	Alopecia	ED70	Phase 2	[3]
Belcesiran	DMLMIGI	Alpha-1 antitrypsin deficiency	5C5A	Phase 2	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
SERPINA1 messenger RNA (SERPINA1 mRNA)	TT2L4TV	A1AT_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05677971) A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis. U.S.National Institutes of Health.
2	Fazirsiran for Liver Disease Associated with Alpha(1)-Antitrypsin Deficiency. N Engl J Med. 2022 Aug 11;387(6):514-524.
3	Clinical pipeline report, company report or official report of Arrowhead Pharmaceuticals.
4	Clinical pipeline report, company report or official report of Dicerna Pharmaceuticals